142 related articles for article (PubMed ID: 35188340)
1. Pattern and predictors of sites of relapse in neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project.
Vo KT; DuBois SG; Neuhaus J; Braunstein SE; Weil BR; Naranjo A; Irtan S; Balaguer J; Matthay KK
Pediatr Blood Cancer; 2022 Sep; 69(9):e29616. PubMed ID: 35188340
[TBL] [Abstract][Full Text] [Related]
2. Clinical and biological features prognostic of survival after relapse or progression of INRGSS stage MS pattern neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project.
Campbell K; Kao PC; Naranjo A; Kamijo T; Ramanujachar R; London WB; DuBois SG
Pediatr Blood Cancer; 2023 Feb; 70(2):e30054. PubMed ID: 36316811
[TBL] [Abstract][Full Text] [Related]
3. Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project.
London WB; Castel V; Monclair T; Ambros PF; Pearson AD; Cohn SL; Berthold F; Nakagawara A; Ladenstein RL; Iehara T; Matthay KK
J Clin Oncol; 2011 Aug; 29(24):3286-92. PubMed ID: 21768459
[TBL] [Abstract][Full Text] [Related]
4. Clinical, biologic, and prognostic differences on the basis of primary tumor site in neuroblastoma: a report from the international neuroblastoma risk group project.
Vo KT; Matthay KK; Neuhaus J; London WB; Hero B; Ambros PF; Nakagawara A; Miniati D; Wheeler K; Pearson AD; Cohn SL; DuBois SG
J Clin Oncol; 2014 Oct; 32(28):3169-76. PubMed ID: 25154816
[TBL] [Abstract][Full Text] [Related]
5. Significance of MYCN amplification in international neuroblastoma staging system stage 1 and 2 neuroblastoma: a report from the International Neuroblastoma Risk Group database.
Bagatell R; Beck-Popovic M; London WB; Zhang Y; Pearson AD; Matthay KK; Monclair T; Ambros PF; Cohn SL;
J Clin Oncol; 2009 Jan; 27(3):365-70. PubMed ID: 19047282
[TBL] [Abstract][Full Text] [Related]
6. [Clinical characteristics and prognosis of high-risk neuroblastoma with bone marrow metastasis in children].
Fan HJ; Huang C; Su Y; Wang XD; Zhou YC; Duan C; Zhao W; Zhao Q; Jin M; Ma XL
Zhonghua Er Ke Za Zhi; 2019 Nov; 57(11):863-869. PubMed ID: 31665841
[No Abstract] [Full Text] [Related]
7. Prognostic value of the stage 4S metastatic pattern and tumor biology in patients with metastatic neuroblastoma diagnosed between birth and 18 months of age.
Taggart DR; London WB; Schmidt ML; DuBois SG; Monclair TF; Nakagawara A; De Bernardi B; Ambros PF; Pearson AD; Cohn SL; Matthay KK
J Clin Oncol; 2011 Nov; 29(33):4358-64. PubMed ID: 21969516
[TBL] [Abstract][Full Text] [Related]
8. Significance of clinical and biologic features in Stage 3 neuroblastoma: a report from the International Neuroblastoma Risk Group project.
Meany HJ; London WB; Ambros PF; Matthay KK; Monclair T; Simon T; Garaventa A; Berthold F; Nakagawara A; Cohn SL; Pearson AD; Park JR
Pediatr Blood Cancer; 2014 Nov; 61(11):1932-9. PubMed ID: 25044743
[TBL] [Abstract][Full Text] [Related]
9. Central nervous system relapse in high-risk stage 4 neuroblastoma: The HR-NBL1/SIOPEN trial experience.
Berlanga P; Pasqualini C; Pötschger U; Sangüesa C; Castellani MR; Cañete A; Luksch R; Elliot M; Schreier G; Kropf M; Morgenstern D; Papadakis V; Ash S; Ruud E; Brock P; Wieczorek A; Kogner P; Trahair T; Ambros P; Boterberg T; Castel V; Valteau-Couanet D; Ladenstein R
Eur J Cancer; 2021 Feb; 144():1-8. PubMed ID: 33316634
[TBL] [Abstract][Full Text] [Related]
10. Metastatic neuroblastoma confined to distant lymph nodes (stage 4N) predicts outcome in patients with stage 4 disease: A study from the International Neuroblastoma Risk Group Database.
Morgenstern DA; London WB; Stephens D; Volchenboum SL; Hero B; Di Cataldo A; Nakagawara A; Shimada H; Ambros PF; Matthay KK; Cohn SL; Pearson AD; Irwin MS
J Clin Oncol; 2014 Apr; 32(12):1228-35. PubMed ID: 24663047
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive evaluation of context dependence of the prognostic impact of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project.
Campbell K; Shyr D; Bagatell R; Fischer M; Nakagawara A; Nieto AC; Brodeur GM; Matthay KK; London WB; DuBois SG
Pediatr Blood Cancer; 2019 Aug; 66(8):e27819. PubMed ID: 31115156
[TBL] [Abstract][Full Text] [Related]
12. Association of image-defined risk factors with clinical features, tumor biology, and outcomes in neuroblastoma: a single-center retrospective study.
Yang DD; Liu C; Gao J; Hu QJ; Liang Y; Liu J
Eur J Pediatr; 2023 May; 182(5):2189-2196. PubMed ID: 36856889
[TBL] [Abstract][Full Text] [Related]
13. Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: a children's cancer group study.
Perez CA; Matthay KK; Atkinson JB; Seeger RC; Shimada H; Haase GM; Stram DO; Gerbing RB; Lukens JN
J Clin Oncol; 2000 Jan; 18(1):18-26. PubMed ID: 10623689
[TBL] [Abstract][Full Text] [Related]
14. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report.
Cohn SL; Pearson AD; London WB; Monclair T; Ambros PF; Brodeur GM; Faldum A; Hero B; Iehara T; Machin D; Mosseri V; Simon T; Garaventa A; Castel V; Matthay KK;
J Clin Oncol; 2009 Jan; 27(2):289-97. PubMed ID: 19047291
[TBL] [Abstract][Full Text] [Related]
15. Neuroblastoma in adolescents: the Italian experience.
Conte M; Parodi S; De Bernardi B; Milanaccio C; Mazzocco K; Angelini P; Viscardi E; Di Cataldo A; Luksch R; Haupt R
Cancer; 2006 Mar; 106(6):1409-17. PubMed ID: 16475209
[TBL] [Abstract][Full Text] [Related]
16. Circulating neuroblastoma cells detected by reverse transcriptase polymerase chain reaction for tyrosine hydroxylase mRNA are an independent poor prognostic indicator in stage 4 neuroblastoma in children over 1 year.
Burchill SA; Lewis IJ; Abrams KR; Riley R; Imeson J; Pearson AD; Pinkerton R; Selby P
J Clin Oncol; 2001 Mar; 19(6):1795-801. PubMed ID: 11251011
[TBL] [Abstract][Full Text] [Related]
17. Managing local-regional failure in children with high-risk neuroblastoma: A single institution experience.
Dove AP; Manole BA; Wakefield DV; Cross SJ; Doubrovin M; Shulkin BL; Merchant TE; Davidoff AM; Furman WL; Krasin MJ; Santana VM; Lucas JT
Pediatr Blood Cancer; 2018 Dec; 65(12):e27408. PubMed ID: 30270551
[TBL] [Abstract][Full Text] [Related]
18. A new risk score for patients after first recurrence of stage 4 neuroblastoma aged ≥18 months at first diagnosis.
Kreitz K; Ernst A; Schmidt R; Simon T; Fischer M; Volland R; Hero B; Berthold F
Cancer Med; 2019 Dec; 8(17):7236-7243. PubMed ID: 31631570
[TBL] [Abstract][Full Text] [Related]
19. The recurrence patterns of stages I, II and III neuroblastoma: experience with 77 relapsing patients.
Berthold F; Hero B; Breu H; Christiansen H; Erttmann R; Gnekow A; Herrmann F; Klingebiel T; Lampert F; Müller-Weihrich S; Weinel P
Ann Oncol; 1996 Feb; 7(2):183-7. PubMed ID: 8777176
[TBL] [Abstract][Full Text] [Related]
20. Factors associated with recurrence and survival length following relapse in patients with neuroblastoma.
Basta NO; Halliday GC; Makin G; Birch J; Feltbower R; Bown N; Elliott M; Moreno L; Barone G; Pearson AD; James PW; Tweddle DA; McNally RJ
Br J Cancer; 2016 Oct; 115(9):1048-1057. PubMed ID: 27701387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
